[Form 4] Silence Therapeutics Plc American Depository Share Insider Trading Activity

Rhea-AI Filing Summary

Silence Therapeutics plc (SLN) – Form 4 insider activity

Director and more-than-10% shareholder Richard Ian Griffiths reported a series of open-market purchases of the company’s American Depositary Shares (ADS) between 7 and 9 July 2025.

• 07 Jul 2025: 7,937 ADS at $5.65
• 08 Jul 2025: 24,387 ADS at $5.94
• 09 Jul 2025: 30,133 ADS at $6.00

The three trades total 62,457 ADS. Each ADS is convertible into three ordinary shares, equating to 187,371 ordinary shares added to his stake.

Following the last transaction, Griffiths’ direct beneficial ownership stands at 11,687,365 ADS. All transactions were coded “P” (purchase) and no dispositions or derivative exercises were reported. No Rule 10b5-1 trading plan was indicated.

The filing signals continued accumulation by a key insider but contains no additional financial or operational disclosures.

Positive

• Insider confidence: A director and >10% shareholder increased his stake by 62,457 ADS, signalling continued confidence.
• No dispositions: Only purchases were reported; no sales or option exercises that might offset the positive signal.

Negative

• None.

Insights

Financial Analyst

TL;DR: 10% holder buys 62k SLN ADS at market prices; a modestly positive but not material signal.

Griffiths’ purchases add roughly 0.5% to his already large position, taking him to 11.7 million ADS. The transactions were small relative to average daily volume and do not meaningfully alter the ownership structure, yet insider buying—especially from a long-term, high-percentage holder—tends to be interpreted as confidence in future prospects. No sales, option exercises, or 10b5-1 plan disclosures were noted, reinforcing the voluntary nature of the buys. From a valuation perspective the dollar outlay (≈ $370 k) is immaterial to corporate finances and therefore market impact is likely limited.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Griffiths Richard Ian

(Last) (First) (Middle)

FLOOR 1 LIBERATION STATION

ESPLANADE

(Street)

ST HELIER Y9 JE2 3AS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Silence Therapeutics plc [ SLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	$5.65	07/07/2025		P		7,937		(1)	(1)	Ordinary Shares	23,811	(1)	11,632,845	D
American Depositary Shares	$5.94	07/08/2025		P		24,387		(1)	(1)	Ordinary Shares	73,161	(1)	11,657,232	D
American Depositary Shares	$6	07/09/2025		P		30,133		(1)	(1)	Ordinary Shares	90,399	(1)	11,687,365	D

Explanation of Responses:

1. Each American Depositary Share ("ADS") is immediately convertible into three ordinary shares for no consideration and has no expiration date.

	/s/ Richard Ian Griffiths	07/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Silence Therapeutics (SLN) ADS did Richard Ian Griffiths purchase?

He bought 62,457 ADS over three consecutive trading days.

What prices were paid for the SLN ADS?

Prices ranged from $5.65 to $6.00 per ADS.

What is the insider's total beneficial ownership after the trades?

Griffiths now directly owns 11,687,365 ADS.

Do the transactions involve a Rule 10b5-1 trading plan?

The Form 4 does not indicate that the purchases were made under a Rule 10b5-1 plan.

How many ordinary shares do the purchased ADS represent?

Because each ADS equals three ordinary shares, the purchases correspond to 187,371 ordinary shares.

Were any securities sold in these Form 4 transactions?

No. All reported transactions were coded "P" (purchase); no dispositions were reported.